These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28072862)

  • 1. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis.
    Kim HJ; Sun HY; Choi H; Park JY; Bae JH; Doo SW; Yang WJ; Song YS; Ko YM; Kim JH
    PLoS One; 2017; 12(1):e0169248. PubMed ID: 28072862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis.
    Filson CP; Hollingsworth JM; Clemens JQ; Wei JT
    J Urol; 2013 Dec; 190(6):2153-60. PubMed ID: 23727412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms.
    Cho S; Kwon SS; Lee KW; Yoo TK; Shin DG; Kim SW; Bae JH; Choi H; Kim YH
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28508455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction.
    Pang R; Zhou XY; Wang X; Wang B; Yin XL; Bo H; Jung JH
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD012336. PubMed ID: 33567116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
    Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
    Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
    Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW
    Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment for male lower urinary tract symptoms with anticholinergic and alpha-blockers.
    Gomelsky A; Kelly EF; Dalton DC
    Curr Opin Urol; 2018 May; 28(3):277-283. PubMed ID: 29432226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
    World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms.
    Shin YS; Zhang LT; Zhao C; Kim YG; Park JK
    Clin Interv Aging; 2014; 9():1021-30. PubMed ID: 25031529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms.
    Park YH; Kim TH; Lee SW; Chung BH; Cho JS; Lee JY
    Low Urin Tract Symptoms; 2017 May; 9(2):75-81. PubMed ID: 28394492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H; Zong H; Cui Y; Li N; Zhang Y
    J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Garimella PS; Fink HA; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Effects of Oral Supplementation of Gamma-Cyclodextrin Curcumin Complex in Male Patients with Moderate-To-Severe Benign Prostatic Hyperplasia-Related Lower Urinary Tract Symptoms.
    Crocerossa F; Cantiello F; Bagalá L; Sicoli F; Carbonara U; Manfredi C; Falagario U; Veccia A; Pandolfo SD; Napolitano L; Ferro M; Di Dio M; Mondaini N; Damiano R
    Urol Int; 2023; 107(10-12):924-934. PubMed ID: 37939691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
    Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
    PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interest of a systematic assessment of the treatment of the lower urinary tract symptoms in the management of benign prostatic hypertrophy in general practice (1380 patients) - Study EVALURO].
    Descazeaud A; Coloby P; De La Taille A; Kouri G; Mallet R; Rossi D; Rozet F; Zerbib M; Carrois F
    Prog Urol; 2019 Feb; 29(2):116-126. PubMed ID: 30665818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, randomized, open-label, parallel trial comparing the efficacy of α-blocker or 5α-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Lee KS; Yoo JW; Kim DH; Jeon S; Yang J; Chung BH; Koo KC
    Prostate; 2024 Mar; 84(4):403-413. PubMed ID: 38149792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.